NCT04190823进行中（未招募）1 期
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC98 For Injection in Subjects With Advanced Malignant Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
This study will evaluate the safety, tolerability and pharmacokinetics of RC98 for injeciton in subjects with advanced malignant solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary agreement to provide written informed consent.
- •Male or female, Age ≥ 18 years.
- •Predicted survival ≥ 12 weeks.
- •Diagnosed with histologically or cytologically-confirmed locally advanced or metastatic solid tumors.
- •Measurable lesion according to RECIST 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment:
- •Cardiac ejection fraction ≥ 50 %. Hemoglobin ≥ 90g/L; Absolute neutrophil count ≥ 1.5×10^9 /L Platelets ≥ 100×10^9 /L; Total bilirubin ≤ 1.5× ULN and ≤ 1.5× ULN with hepatic metastasis; AST and ALT ≤ 2.5×ULN and ≤ 5 x ULN with hepatic metastasis; Serum creatinine ≤1.5×ULN; INR, APTT and PT ≤ 1.5× ULN; TSH or FT4 or FT3 in (1±10%) ULN.
- •All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception.
- •Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
排除标准
- •Known hypersensitivity to the components of RC98 for injection.
- •Toxicity of previous anti-tumor treatment not recovered to CTCAE Grade 0-1 (with exception of Grade 2 alopecia).
- •Pleural or abdominal effusion with clinical symptoms that requires ongoing treatment.
- •History of receiving any research drug treatment within 4 weeks prior to trial treatment.
- •History of major surgery, chemotherapy or radiotherapy within 4 weeks of planned start of trial treatment.
- •History of arterial / venous thrombosis events, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurred within 6 months before study medication.
- •NYHA Class III heart failure.
- •Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- •Currently known active infection with HIV or tuberculosis.
- •Diagnosed with HBsAg , HBcAb positive and HBV DNA copy positive, or HCVAb positive.
- •Uncontrolled hypertension, diabetes, pulmonary fibrosis, acute lung disease, interstitial lung disease, or cirrhosis;
- •Treated with corticosteroids or other immunosuppressants for the autoimmune disease within 14 days prior to the study treatment.
- •Existing active, or have experienced autoimmune diseases that may recur (eg: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis Disease, etc.) or subjects with these disease risks.
- •Pregnancy or lactation.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial.
- •Presence of primary tumors of the nervous system, brain metastases and / or cancerous meningitis.
- •History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
- •History of receiving immune-enhancing therapy (eg, alpha-interferon, interleukin-2), hormone therapy, traditional Chinese medicine treatment, or palliative radiotherapy for bone metastases within 2 weeks of planned start of trial treatment.
- •Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
研究组 & 干预措施
RC98
Experimental
干预措施: RC98 (Drug)
结局指标
主要结局
Adverse events
时间窗: From the day of ICF sign to 28 days after the day of the last treatment
Adverse events was assessed by investigator(s) according to NCI-CTCAE v4.03
Maximum Tolerated dose of RC98
时间窗: 12 months
The dose level in which \>= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.
次要结局
- Objective Response Rate(ORR)(15 months)
- Progression Free Survival (PFS)(15 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsSolid TumorsNCT02881138RemeGen Co., Ltd.24
已完成
1 期
A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsSolid TumorNCT04617314RemeGen Co., Ltd.67
Unknown
1 期
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid TumorsSolid TumorNCT06215846Beijing Bio-Targeting Therapeutics Technology Co., Ltd12
已完成
1 期
A Study of RC48-ADC in Subjects With Advanced Breast CancerAdvanced Breast CancerNCT03052634RemeGen Co., Ltd.112
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.Healthy VolunteersNCT04958291Celgene25